1. Medtech Insight
  2. >>Business
  3. >>Deals

9 + 11 = Possible 3: Can A Stryker-Boston Scientific Combo Work?

 
• By Tina Tan

Unconfirmed rumors of Stryker having approached Boston Scientific about a takeover bid raised eyebrows all around, not least because the move – reported on June 11 – was so unexpected. But would a combination of the medtech industry's No. 9 and No. 11, to create a broad-scale portfolio with very little product overlap, make strategic sense? Reactions have been mixed.

Question marks
Rumors of a Stryker/Boston Scientific merger have raised questions about whether a bigger combined company will work

When the rumors about Stryker Corp. making a play for Boston Scientific Corp. first emerged on June 11, the reaction was of unified surprise. The report, by the Wall Street Journal citing sources close to the matter, led to Boston Scientific's share value jumping 17% during intraday trading and Stryker's shares dipping slightly, while market spectators tried to figure out if a possible merger between the industry's No. 9 (Stryker, its ranking in the MTI 100 league table) and No. 11 (Boston Scientific) could actually work.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 
• By Brian Bossetta

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.

Roche Diagnostics Hit By China Reforms As Q1 Sales Remain Flat

 
• By Shubham Singh

While Roche continues to view China as a strategic growth market, a sharp 23% decline in Chinese diagnostics sales offset gains in other regions and segments. Despite near-term headwinds, Roche is betting on strong instrument placement growth across its Core Lab, Molecular, and Near Patient Care segments to fuel future demand for consumables and services–key components of its long-term medtech strategy.

Roche’s $50Bn Bet On US Manufacturing: Tariff Shield But Cash Flow Strain

 
• By Shubham Singh

New continuous glucose monitoring manufacturing site in Indiana is part of Roche’s plan to boost its US presence. Roche’s launch of Accu-Chek SmartGuide system last year with AI-powered prediction capabilities puts it as a key differentiator from competitors such as Abbott and Dexcom.